ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Biophytis

Biophytis (ALBPS)

0.2999
-0.0021
(-0.70%)
Cerrado 05 Febrero 10:30AM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.2999
Postura de Compra
0.297
Postura de Venta
0.30
Volume Operado de la Acción
143,139
0.296 Rango del Día 0.308
0.0021 Rango de 52 semanas 1.40
Capitalización de Mercado [m]
Precio Anterior
0.302
Precio de Apertura
0.296
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
97,799
Acciones en circulación
295,702,507
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-5.38
Beneficio por acción (BPA)
-0.06
turnover
-
Beneficio neto
-17.03M

Acerca de Biophytis

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Paris, Paris, Fra
Fundado
-
Biophytis is listed in the Biological Pds,ex Diagnstics sector of the Euronext with ticker ALBPS. The last closing price for Biophytis was 0.30 €. Over the last year, Biophytis shares have traded in a share price range of 0.0021 € to 1.40 €.

Biophytis currently has 295,702,507 shares in issue. The market capitalisation of Biophytis is 89.30 € million. Biophytis has a price to earnings ratio (PE ratio) of -5.38.

ALBPS Últimas noticias

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company...

Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patien...

PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug...

Biophytis Announces Results of 2019 Annual General Meeting of Shareholders

All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE...

Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)

Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019...

Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer

PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Announces Publication of its 2018 Annual Report

Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019...

Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...

Biophytis Reports Annual 2018 Financial Results and Provides Operational Update

Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...

Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Re...

PARIS, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel therapeutics for age-related...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.00893.058419243990.2910.31850.29021022430.30107558DE
4-0.1211-28.76484560570.4210.460.252208560.29346423DE
120.00592.006802721090.2940.460.25977990.30035501DE
26-0.2001-40.020.50.840.25742200.3837005DE
520.29526280.851063830.00471.40.002156067980.00702884DE
156-0.1151-27.7349397590.4151.40.002154471530.02506527DE
2600.133980.66265060240.1662.730.002147301000.27505672DE

ALBPS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Biophytis?
El precio actual de las acciones de Biophytis es 0.2999 €
¿Cuántas acciones de Biophytis están en circulación?
Biophytis tiene 295,702,507 acciones en circulación
¿Cuál es la capitalización de mercado de Biophytis?
La capitalización de mercado de Biophytis es EUR 89.3M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Biophytis?
Biophytis ha negociado en un rango de 0.0021 € a 1.40 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Biophytis?
El ratio precio/beneficio de Biophytis es -5.38
¿Cuál es la moneda de reporte de Biophytis?
Biophytis presenta sus resultados financieros en EUR
¿Cuál es el último beneficio anual de Biophytis?
El último beneficio anual de Biophytis es EUR -17.03M
¿Cuál es la dirección registrada de Biophytis?
La dirección registrada de Biophytis es 14 AVENUE DE L’OPERA, PARIS, PARIS, 75001
¿Cuál es la dirección del sitio web de Biophytis?
La dirección del sitio web de Biophytis es www.biophytis.com
¿En qué sector industrial opera Biophytis?
Biophytis opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MLCOTCoretech 5
0.044 €
(46.67%)
142.41k
ALNMGNetMedia Group
2.00 €
(42.86%)
21.24k
ALALOAcheterLouerFR
0.032 €
(24.03%)
1.9M
MHMMyHotelMatch
0.41 €
(17.48%)
29.36k
VLAValneva SE
3.09 €
(16.96%)
4.57M
BIODSBiosynex DS
0.0008 €
(-96.14%)
464.1k
MLUMGUmalis Group
1.32 €
(-38.32%)
1.53k
TUVDSBio UV Group DS
0.0327 €
(-34.60%)
1.19M
ALVIOValerio Therapeutics
0.0586 €
(-24.58%)
1.43M
ALTROTronic s Microsystems
4.10 €
(-23.36%)
40
ATOAtos SE
0.0021 €
(0.00%)
181.59M
BCPBanco Comercial Portugues SA
0.493 €
(-0.28%)
55.02M
ALMASMastrad
0.0268 €
(16.52%)
19.73M
ALTDTonner Drones
0.013 €
(10.17%)
14.47M
ALAGOEPango SA
0.278 €
(-12.58%)
11.3M
SSKILLZ1 SSKILLZ1 1 minuto hace
GEN

Reported last week, I thought the raising of the bottom end of guidance was a plus. And I really continue to like how they continue to add customers as well. About a 12-15% EPS grower consistently, and I think earnings will probably be close to $2.50 next fy which lets face it isn
Edward Edward 1 minuto hace
So you changed you mind. Back to lose more.

lifeonthefarm



Wednesday, December 11, 2024 1:29:12 PM
Post# of 93746
I GIVE UP...IM GONE...GL all
VXIT
mars2063 mars2063 1 minuto hace
0x0=0
Rdar scammed = 0,0000000000
RDAR
vlispxpert vlispxpert 1 minuto hace
EYEN, little lower, low $2's imo...but I'm trying to avoid r/s abusers..their days are numbered with new rule...how do you spot an abuser:

https://schrts.co/SXYPSRiE

use weekly, if price is abnormally high (in other words, you know price was never $600+ in this case, th
FDMT
4u2nv2 4u2nv2 2 minutos hace
MCIC Market View mid morning report. The PPS moving up as the ask bounces up to a penny on low volume. Small sell order is at .0041 for 200,000 shares. 10,000 showing at .005 and 300,000 at .01C. Next considerable block to buy is 300,000 at .016C. Stay tuned for live discussion on MCIC - Only on the
MCIC
Cringe Cringe 2 minutos hace
u guys are like manic AI robots lol, literally buy the dip worked out AGAIN. Free money transaction #5050505050503
FNMA
DavidLeeRoth DavidLeeRoth 2 minutos hace
Didn’t you just ask the company that on X? Why ask me? ASII WINNING💰💰
ASII
devil dog 96 devil dog 96 3 minutos hace
More no proof scam theory clown🤡 show promo filler. I love the effort! 😆 LMAO

" Don’t get Conned by the CONdog96 🤡™ clown. "

The no proof scam theory promo is a total sham!!

https://investorshub.advfn.com/uimage/uploads/2024/6/21/j
CRSM
BeachBum BeachBum 3 minutos hace
50 mil bid
PSRU
Penny Stocks 2.0 Penny Stocks 2.0 3 minutos hace
She's getting real thin....002 today? 
HADV
abazaba375 abazaba375 3 minutos hace
SMCE 200 DMA on the weekly @ .0032 break that and we're off https://x.com/tvestor3/status/1887180820852412474?s=46
SMCE
TrendTrade2016 TrendTrade2016 3 minutos hace
HYPR HERE COMES THE VOLUME
HYPR
johnlconfer johnlconfer 4 minutos hace
Xoom not sure on all of it but it appears higher cost debt is being paid off. Wasn’t JPM a large holder of Ps and Us.

Semper Fi
JPM
BigJuan BigJuan 4 minutos hace
Yep solid looking company. Love this action here!
STRH
MiamiGent MiamiGent 4 minutos hace
"Club Med"
BBANBOB BBANBOB 4 minutos hace
Fred
at the 500 mill I have suggested it is $17.41 so we are both in the ball park
Now lets just hope it come to fruition.

stuck on $420mm, total............$14.20 per.........but outside chance of all of LIBOR....=...$23.....purrrrrrrr.........the $364mm, settlemen
GrandAdmiralThrawn GrandAdmiralThrawn 4 minutos hace
Well well well, LFG!!!
HADV
primecomm primecomm 4 minutos hace
$GRLF= No R/S+$2.3M Rev+Buybacks+OTCQB= .001+++++
GRLF
ThunderousSeer8 ThunderousSeer8 4 minutos hace
There is no shareholder support here from this company. He's jaded by the fact that we're now where we were in April of last year (0.0008) before this reverse merger even took place. That's bad. Really bad. The unemployed still need to become employable but they may have been right here.
RDAR
D-man4 D-man4 4 minutos hace
Why doesn't Cohen release a statement about the situation with a PR he's already supposedly paid for not being released?
Sounds suspiciously like this in Cohens issue and not Access Wires issue. 
AW's business model is pretty simple. People pay them and they push a PR out to all availa
AZRH
Carjockey2 Carjockey2 4 minutos hace
Extremely knowledgeable which I guess you would expect with 3 separate degrees. Just one of the reasons I'm in here or should I say back in here.

Or wait ...should I listen to those with obvious agendas?

>>>@NoMoDo I just want to say your input is very well appreciated
HMBL
Bubae Bubae 4 minutos hace
This ticker is one share printing machine with some ugly notes. There is a 13G filed on January 28th for Apollo Management Group reporting 252,100,840 shares or 8.75% ownership of the OS. The colorful terms allows conversion at any time, convertible at a steep discount to 30 days prior to the agree
ASII
Chartmaster Chartmaster 5 minutos hace
Who's Marc? And why should I care? It's the OTC
TMGI
arizona1 arizona1 5 minutos hace
Anyway, I"m not the one who's going to enjoy a beachfront villa in Gaza, I'm appalled by the concept, but you guys helped make that idea possible.

No, it was your genocidal maniacs in Israel who have been planning this for a very long time. Ethnic cleansing was always their goal and
uss_longhold81 uss_longhold81 5 minutos hace
1 fraction of a penny from zero. 


Insert badger, patriotic quotes, ceo skull rings, and shady online pumpers!!

Turd city
ASTA